Mapi Pharma Ltd.

Viatris and its partner Mapi Pharma will have to wait a little longer before they can move ahead with their proposed once-monthly glatiramer acetate product, a follow-on to Teva’s Copaxone treatmen

Mapi Pharma’s Phase III clinical trial for its GA Depot long-acting injectable version of Copaxone (glatiramer acetate) and its generic equivalents, out-licensed to Viatris , is progressing ahead of

Mylan has agreed to invest a further $20m to support trials for a monthly glatiramer acetate depot product being developed by partner Mapi Pharma for the US market. The relapsing-remitting multiple

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GSK Teams With Ideaya On Synthetic Leth